Sign inJoin waitlistJoin the waitlist

Olumide Gbolahan

Chief of Service, Hematology and Oncology, Grady Health System · Emory University School of Medicine

Credentials: · · · · · · ·

History

Hematology and Oncology Division · Emory University School of Medicine
Present
Grady Health System Division · Emory University School of Medicine
Present
Emory University School of Medicine
Present

Hematology and Medical Oncology
Indiana University School of Medicine
2015–2018
Internal Medicine
Morehouse School of Medicine
2012–2013
MBBS from University of Ibadan
UNIV OF IBADAN COLL OF MED, IBADAN, OYO STATE, NIGERIA
2002–2006

Research

NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2021
Journal of the National Comprehensive Cancer Network · 2021 · 196 citations
Locoregional and systemic therapy for hepatocellular carcinoma
Review · Journal of Gastrointestinal Oncology · 2017 · First of 6 authors · 69 citations
Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX
Clinical Cancer Research · 2018 · 67 citations

GW
Grant Williams
16 papers
Ravi Paluri
12 papers
Smita Bhatia
11 papers
Smith Giri
10 papers · 1 as a fellow
Bert O'Neil
7 papers
Darryl Outlaw
7 papers · 3 as a fellow
Andrew McDonald
6 papers
Olatunji Alese
6 papers
CH
Christian Harmon
5 papers
LN
Lakshminarayanan Nandagopal
4 papers
Moh'd Khushman
4 papers
NS
Neda Hashemi Sadraei
4 papers · 2 as a fellow

Clinical trials

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment
Principal investigator · Recruiting · Phase 2
Emory University
2026–2029
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
Principal investigator · Recruiting · Phase 2
Emory University
2026–2027
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
Principal investigator · Terminated · Phase 2
Emory University
2022–2025
2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers
Principal investigator · Recruiting · Phase 2
Emory University
2019–2026